

Pulmonary Artery Involvement in Patients with Takayasu Arteritis

Key Indexing Terms: TAKAYASU ARTERITIS, PULMONARY ARTERY, PULMONARY HYPERTENSION, PROGNOSIS

From the Fuwai Hospital, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 Beilishi Road, Beijing 100037, China

This study is supported by the National Natural Science Foundation of China (grant no. 30770859 and 81170285) and CAMS innovation Fund for Medical Science(CIFMS), 2017-12M-2-002.

Conflict of interest: None

Yanru He, MD; Naqiang Lv, MD, PhD; Aimin Dang, MD, PhD; Nan Cheng, MD; Fuwai Hospital, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College

Address correspondence to Dr. Aimin Dang, Fuwai Hospital, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 Beilishi Road, Beijing 100037, China. Email: amdangfw@163.com and amdang@fuwaihospital.org

Running title: PAI in TA

This article has been accepted for publication in The Journal of Rheumatology following full peer review. This version has not gone through proper copyediting, proofreading and typesetting, and therefore will not be identical to the final published version. Reprints and permissions are not available for this version. Please cite this article as doi 10.3899/jrheum.190045. This accepted article is protected by copyright. All rights reserved.

ABSTRACT

Objective. This study was performed to explore the clinical manifestations and long-term prognosis in patients with Takayasu arteritis (TA) with pulmonary artery involvement (PAI).

Methods. The medical records of 194 patients with TA who underwent traditional catheter angiography or computed tomography of pulmonary artery from 2009 to 2016 were retrospectively reviewed. The clinical manifestations, angiographic features, and mortality of 128 patients with TA with PAI were further analyzed.

Results. Patients with TA with PAI had a higher risk of pulmonary hypertension (PH) than patients with TA alone (61.7% vs. 7.6%, $p<0.001$). Patients with PAI and PH more frequently developed dyspnea, hemoptysis, and lower limbs edema (all $p<0.05$) than those without PH. Patients with PH also had a higher incidence of bilateral PAI (84.8% vs. 34.7%, $p<0.001$) and a higher pulmonary artery obstruction index (23[20–27] vs. 10[6–5], $p<0.001$). Left heart disease was presented in 39 (30.5%) patients with TA with PAI. During the median follow up of 38 (21–58) months, 19 and 2 deaths occurred among patients with and without PH, respectively. Among patients with PAI, the mortality rate was 7 times higher in patients with than without PH ($p=0.009$). Independent predictors of mortality were the disease duration ($p=0.047$), New York Heart Association Class III/IV ($p=0.019$), right ventricular systolic dysfunction ($p=0.019$) and respiratory failure ($p=0.007$).

Conclusion. Patient with TA with PAI have a higher risk of developing PH than patients with TA alone. The presence of PH in patients with PAI increases the risk of mortality.

Key words: Takayasu arteritis (TA); pulmonary artery (PA); pulmonary hypertension (PH); Prognosis

Takayasu arteritis (TA) is a chronic granulomatous vasculitis that primarily affects the aorta and its main branches, including the pulmonary artery (PA)^{1,2,3}. The profound inflammatory process in the affected arteries can lead to stenosis, occlusion, aneurysms and end-organ ischemia, thereby increasing the risk of cardiovascular morbidity and mortality.

PA involvement (PAI) is not infrequent, occurring in 20% to 56% of patients with TA according to autopsy reports^{4,5}. However, the pulmonary circulation is often overlooked in the initial assessment of patients with TA. Pulmonary hypertension (PH) is a major complication in the course of TA-associated PAI^{6,7,8,9,10,11,12}. The diagnosis of PH carries a 7-fold higher risk of mortality in many different clinical conditions¹³. Because of the rarity of the disease, few studies have comprehensively investigated the clinical manifestations and long-term outcomes of TA with PAI.

In the present study, we explored the clinical manifestations and long-term prognosis of a relatively large cohort of patients with TA with PAI. The aim of our study was to help clinicians systematically recognize PAI in patients with TA.

MATERIALS AND METHODS

Patients

The medical records of 598 consecutive inpatients diagnosed with TA from January 2009 to December 2016 were retrospectively reviewed. Of 194 patients who underwent traditional catheter angiography or computed tomography (CT) of PA, 128 had PAI. The patients' medical records were retrospectively reviewed for demographic data, clinical symptoms and signs, comorbidities, laboratory test results, echocardiographic parameters, and imaging findings. This research conformed to the ethical guidelines of the 1975 Declaration of Helsinki. The

study protocol was approved by the Ethics Committee of Fuwai Hospital (2010-246).

Diagnosis and classification

TA was classified in accordance with the 1990 American College of Rheumatology (ACR) criteria¹⁴. All patients fulfilled at least 3 of the following 6 criteria: age of <40 years at onset, claudication of the extremities, a decreased brachial artery pulse, a blood pressure difference of > 10 mmHg, bruit over the subclavian arteries or aorta, arteriogram abnormalities¹⁴. The subtypes of systemic artery involvement were classified into 5 types (I, IIa, IIb, III, IV, and V) based on the classification proposed by Numano et al¹⁵.

PAI was defined as the presence of vascular involvement manifested as stenosis, occlusion, dilation or aneurysm formation in either PA. For patients who underwent CT pulmonary angiography, we used the PA obstruction index (PAOI) to quantify the degree of PA obstruction¹⁶. The PAOI can be expressed as $\Sigma (n \times d) / 40 \times 100$, where n is the value of the proximal obstruction in the PA tree equal to the number of segmental branches arising distally (minimum, 1; maximum, 20), and d is the degree of obstruction (minimum, 0; maximum, 2)¹⁶. According to routine clinical practice at Fuwai Hospital, each PA imaging examination was systematically assessed by qualified chest radiologists. The results were further reviewed by senior chest radiologists.

All the 194 patients with TA in our study underwent echocardiography by certified echocardiologist. The result of each echocardiographic examination was also systematically reviewed by a senior echocardiologist. According to the European Society of Cardiology/European Respiratory Society guidelines for PH, patients with PAI were considered to have a high probability of PH if their peak tricuspid regurgitation velocity (TRV) was > 3.4 m/s with

or without the presence of other echo “PH signs”¹⁷. Patients with a peak TRV of 2.9 to 3.4 m/s and additional echo signs suggestive of PH were also considered to have a high probability of PH¹⁷. The PA systemic pressure is estimated based on the peak TRV, taking the right atrial pressure in to account according to the simplified Bernoulli equation¹⁷. Based on the echocardiographic measurements, left heart disease (LHD) was considered to be present in patients with left atrial or left ventricular enlargement, left ventricular hypertrophy, moderate or severe left heart valve disease, and a left ventricular ejection fraction of < 50%.

Outcome and follow up

The major outcome was all-cause mortality. Patients were followed up by consulting the hospital records or performing the clinic interviews or telephone surveys. The follow-up duration was defined as the length of time from the first admission to March 2018. For the patents who died during follow-up, the follow-up duration was defined as the length of time in months from the first admission to the time of death. Patients who were lost to follow-up were censored at their last available follow-up visit.

Statistical analysis

Continuous variables with a normal distribution are presented as mean and standard deviation. The differences between groups were analyzed by Student’s t test. Continuous variables with a non-normal distribution are expressed as median and interquartile range. Comparisons between groups were performed using the Mann–Whitney U test. Qualitative variables are presented as number (percentage). The chi-square test or Fisher’s exact test was used to compare the differences. Survival rates were estimated by the Kaplan-Meier method, and differences between groups were assessed by the log-rank test. Univariate and multivariate Cox

proportional hazard regressions were used to detect factors independently associated with mortality. The data analysis was conducted using the SPSS 21.0 statistical package (IBM Corp., Armonk, NY, USA). Figures were presented by GraphPad Prism 6.01 (GraphPad Software, San Diego, CA, USA).

RESULTS

Demographic data and clinical characteristics between patients with TA with and without PAI

The demographic and clinical characteristics of patients with and without PAI are presented in Table 1. Among the 194 patients included in the current study (185 patients had CT and 54 patients had traditional PA angiography), 65% (120/185) of the patients were confirmed to have PAI by CT, and 98% (53/54) were confirmed to have PAI by traditional PA angiography. In total, 66% (128/194) patients were diagnosed as PAI by CT or PA angiography. The mean age and disease duration of TA in the patients with PAI was 39.2 ± 12.3 years and 60 (24–156) months respectively, with no significant difference compared with patients without PAI. Patients with PAI more frequently developed dyspnea (74.2% vs. 22.7%, $p < 0.001$), hemoptysis (20.3% vs. 3.0%, $p = 0.001$) and leg edema (20.3% vs. 3.0%, $p = 0.001$). Patients with PAI also had an increased risk of developing PH (61.7% vs. 7.6%, $p < 0.001$) and were more often classified into New York Heart Association (NYHA) class III/IV (40.6% vs. 19.7%, $p = 0.003$). The patients with PAI had fewer systemic ischemia-related symptoms and comorbidities such as dizziness (18.0% vs. 34.8%, $p = 0.009$), limb claudication (19.5% vs. 39.4%, $p = 0.003$), hypertension (47.7% vs. 77.3%, $p < 0.001$), and stroke (3.9% vs. 15.2%, $p = 0.005$).

The detailed information regarding systemic artery involvement is shown in Figure 1. Patients with PAI had a lower tendency to have involvement of the renal artery (30.5% vs.

42.4%, $p=0.097$), iliacofemoral artery (9.4% vs. 18.2%, $p=0.078$), and coronary artery (6.3% vs. 13.6%, $p=0.085$). Patients with PAI had a higher tendency to be classified as having angiographic type IIa systemic artery involvement (8.6% vs. 1.5%, $p=0.062$, Table1). However, the differences in the distribution of the involved systemic arteries and angiographic classification were not statistically significant between the 2 groups (all $p>0.05$).

Angiography features of PA lesion.

Most patients with PAI (84, 65.6%) had bilateral involvement. Among the other 44(34.4%) patients with unilateral involvement, right and left PAI was present in 32(25.0%) and 12(9.4%) patients, respectively. The PA trunk was compensatorily enlarged in the patients with PH. The lobar PA (97, 75.8%) was the most commonly involved artery, followed by the main PA (63, 49.2%) and segmental PA (62, 48.4%). The distribution of the involved PAs is shown in Table2. The right upper lobar braches (72, 56.3%) were the most frequently involved region. Multi-branch PAI was more common than single-branch involvement (89.1% vs. 10.9%). Stenosis and occlusion were the most frequent type of lesions. Aneurysm formation and in situ thrombosis in the PA were detected in 4(3.1%) and 5(3.9%) patients, respectively.

Differences between patients with PAI with and without PH

The comparisons between patients with PAI with and without PH are displayed in Table3. Respiratory symptoms were the initial chief complaints in 68 patients (60 in the PH group vs. 8 in the Non-PH group, $p<0.001$). Among the other 60 patients without respiratory symptoms as the initial symptom, 27 patients were diagnosed with PAI within the first year of diagnosis of TA (10 in the PH group vs. 17 in the Non-PH group, $p=0.419$), 7 in the second to third year (0 in the PH group vs. 7 in the Non-PH group, $p=0.086$), and 26 patients after the third year (17

in the PH group vs. 9 in the Non-PH group, $p=0.668$). Unsurprisingly, clinical manifestations such as dyspnea (94.9% vs. 40.8%, $p<0.001$), hemoptysis (26.2% vs. 10.2%, $p=0.025$), leg edema (26.6% vs. 10.2%, $p=0.025$), respiratory failure ($\text{PaO}_2<60\text{mmHg}$, 29.1% vs. 6.1%, $p=0.001$), and NYHA class III/IV (59.5% vs. 10.2%, $p<0.001$) were more common among patients with than without PH. In addition, patients with PH less frequently had an elevated C-reactive protein concentration (reference value, 0–8 mg/L; 22.8% vs. 44.9%, $p=0.009$) and erythrocyte sedimentation rate (reference value, $<20\text{ mm/h}$; 24.1% vs. 40.8%, $p=0.045$).

Comparing with the patients without PH, patients with PH more frequently had bilateral PAI (84.8% vs. 34.7%, $p<0.001$) and a higher PAOI (23 [20–27] vs. 10 [6–15], $p<0.001$). The PAOI was strongly correlated with PA systemic pressure ($r=0.570$, $p<0.001$) as estimated by echocardiography. The numbers of patients in the PH group with abnormal right cardiac structure and function were as follows: 57 (72.2%) had right atrial enlargement, 56 (70.9%) had right ventricular enlargement, and 29 (36.7%) had right ventricular systolic dysfunction (29, 36.7%). Patients with PH less frequently had left ventricular enlargement (8.9% vs. 34.7%, $p<0.001$) and significant aortic regurgitation (5.1% vs. 26.5%, $p=0.001$) than patients without PH.

When we divided all patients with TA with PAI according to the presence of PH and LHD, 21 patients were assigned to the Non-PH and Non-LHD group (Group 1), 28 to the Non-PH and LHD group (Group 2), 68 to the PH and Non-LHD group (Group 3), and 11 to the PH and LHD group (Group 4).

Treatment

Corticosteroids were administered to 61 (77.2%) and 42 (85.7%) patients with PAI among those

with and without PH ($p=0.238$). Immunosuppressants were additionally prescribed to 14 patients with no significant differences between patients with and without PH (13.9% vs. 6.1%, $p=0.169$). No patients in our cohort were treated with biologics. Twenty-five (19.5%) patients did not receive corticosteroids or immunosuppressive agents because their condition was judged inactive. Among the 79 patients with PH, 46 (58.2%) patients were prescribed PH-targeted agents. There were 9 patients with PH-targeted agents and 10 patients without PH-targeted agents died during follow up respectively, and their survival was not significantly improvement by the PH-targeted agents ($p=0.414$).

Percutaneous transluminal pulmonary angioplasty (PTPA) was performed in 28 patients at the first admission or during follow-up. The main indication for PTPA was severe PA stenosis combined with severe PH. One patient with occlusion in the right main PA and stenosis of 90% in the left lower lobar PA died of reperfusion pulmonary edema after PTPA. Among the other 27 patients, the mean PA pressure was decreased from 53 ± 17 to 41 ± 13 mmHg ($p<0.001$) and 6 of these patients had a mean PA pressure of <30 mmHg after PTPA procedure.

Long-term survival and its predictors

During the median follow-up of 38(21–58) months, 12 patients were lost to follow-up and 21 of the remaining 116 patients died. The causes of death among the 19 patients with PH were as follows: heart failure in 15, sudden cardiac death in 2, massive cerebral infarction in 1, and post-PTPA reperfusion lung injury in 1 patient. The causes of death in the 2 patients without PH were as follows: severe aortic regurgitation in 1 and severe mitral-aortic regurgitation in 1.

The 1-, 3-, and 5- year survival rate in patients with PAI with and without PH were 93.3% vs. 98.0%, 82.3% vs. 98.0%, and 69.0% vs. 92.5%, respectively. Kaplan–Meier analysis

showed that patients with PAI with PH had a higher probability of mortality during follow-up (log rank test: $p=0.002$) (Figure 2A). The patients in the Non-PH and Non-LHD group (Group 1) had a much better prognosis than the patients with PH (Group 1 vs. Group 3, $p=0.012$; Group 1 vs. Group 4, $p=0.002$) (Figure2B). Among the 39 patients with LHD, those with PH (Group 4) had a significantly higher mortality rate than those without PH (Group 2) ($p=0.029$) (Figure2B). Among the 79 patients with PH, no differences were found in mortality between patients with LHD (Group 4) and without LHD (Group 3) ($p=0.406$) (Figure2B).

In the univariate Cox analyses, the mortality rate was 7 times higher in the patients with PH than without PH (hazard ratio [HR]=7.003, 95% confidence interval [95%CI] =1.637–30.218, $p=0.009$). The multivariate analyses, which included variables associated with mortality in the univariate analysis, showed that the disease duration (HR=1.004, 95%CI=1.001–1.007, $p=0.047$), NYHA class III/IV (HR=4.201, 95%CI=1.269–13.911, $p=0.019$), right ventricular systolic dysfunction (HR=3.189, 95%CI=1.207–8.428, $p=0.019$), and respiratory failure (HR=3.601, 95%CI=1.416–9.154, $p=0.007$) were independently associated with mortality in patients with TA with PAI (Table4).

DISCUSSION

PAI is not rare but the pulmonary circulation is often overlooked in the clinical assessment of TA. According to previous research, when only including patients with TA who have undergone imaging of the PA, the incidence of PAI varied from 33% to 86%^{3,6,18,19,20,21}. In the present study, the ratio of PAI was 66% among the patients who underwent PA angiography and 21.4% among all patients with TA, which is consistent with previous studies.

Patients with PAI are more prone to develop PH than those without PAI. Sari et al.¹² reported

that PH was present in 25.0% of patients with PAI and 7.7% without PAI. In a case review conducted by Toledano et al.⁷, 42.2% of patients with PAI also had PH. In the present study, patients with PAI also had a higher risk of developing PH than those without PAI (61.7% vs 7.6%). Mechanical obstruction of the pulmonary vasculature is the leading mechanism underlying the development of PH in TA associated PAI. Similar to the findings reported by Wang et al.²², the PA pressure was significantly correlated with the extent of PAI in the present study. Additionally, markedly reduction in blood flow of the PA leads to hypoxemia because of ventilation–perfusion mismatch. Wang et al.²² also reported that patients with PH due to PAI were more prone to respond to vasoreactivity testing. This suggests that increased vascular tone in the PA may contribute to increases in the PA pressure. Moreover, the coexistence of LHD might contribute to the development of PH^{12,22}, which occurred in 11 of 79 patients with PAI and PH in our study.

Patients with PH due to TA-associated PAI have a poor prognosis. According to Toledano et al.⁷, the mortality rate was 20.5% in patients with PAI and 33.3% among patients with PH. In a recent Chinese study involving 57 patients with PAI (33 with PH and 24 without PH), all 3 patients who died had PH⁸. In the present study, the risk of mortality was 7 times higher in patients with than without PH during the 38-month follow-up. Additionally, severe complications of PH such as right heart failure, respiratory failure, a poor NYHA class, and a long disease duration were independent predictive factors for mortality among patients with TA-associated PAI.

Because of the poor prognosis of PH in the patients with PAI, pulmonary circulation must be routinely screened in patients with TA in the early stage. Traditional angiography is still the

gold standard for detecting lesions in the PA^{6,19}. However, angiography is an invasive procedure and is therefore frequently replaced by CT and magnetic resonance (MR) angiography, especially in the initial evaluation. CT and MR angiography of the PA can reveal not only stenosis, occlusion, or dilation of the vascular lumen but also thickening of the artery wall^{8,23,24}. MR angiography can also disclose early mural inflammatory signs in the PA by late gadolinium enhancement²⁵. Fluorodeoxyglucose–positron emission tomography (FDG-PET) is a more sensitive modality that can intuitively depict active inflammation of the aorta and PA even before any structural change^{26,27}. The change in the standardized uptake value with FDG-PET can also help with early evaluation of the treatment response²⁸. However, one study showed that FDG-PET may have low power to detect the lesions in small-diameter PAs²⁹. Thus, to clearly evaluate lesions and inflammatory activity in the PA, various imaging modalities may be needed to complement each other.

Echocardiography is a simple and noninvasive imaging modality with which to evaluate the structure and function of the heart and estimate the PA pressure. Echocardiography can also provide information on lesions in the right and left main PA³⁰. In the present study, the prognosis of patients with PAI was also well stratified based on the echocardiography assessment. Therefore, echocardiography should be routinely performed for all patients with TA at the time of the initial evaluation, and subsequent assessment is advocated for patients with a high probability of PH or new-onset symptoms suggesting PH. For patients with a high probability of PH as evaluated by echocardiography, right heart catheterization is necessary to further assess the hemodynamics and confirm the diagnosis of PH¹⁷.

Aggressive stabilization of the disease activity plays a key role in the progression and

Accepted Article

prognosis of TA-associated PAI and PH. In our cohort, patients with a history of corticosteroid therapy tended to have a lower incidence of PH than those without history of corticosteroid (50% vs 67%, $p=0.066$). Immunosuppressants were less frequently prescribed in our study, thus, it was difficult to evaluate their impact on patients with PAI by such limited samples. However, according to Lee et al.³¹, patients with active disease were at high risk of developing PAI and PH. Sari et al¹² also reported that patient with severe or treatment resistant TA had a high risk of PH. Therefore, more widespread use of immunosuppressive agents and biologics might improve the poor prognosis of patients with PAI and PH. PH-targeted drugs were also used but not associated with improvement of survival in our study. However, the therapeutic effect of PH-targeted agents should be further evaluated by a well-designed prospective randomized study and the endpoint should include not only survival but also change in the exercise capacity.

Established PH and stenosis of the PA cannot usually be reversed by medical treatment alone. Pulmonary revascularization is a complementary strategy to restore pulmonary blood flow and should be performed during the inactive disease stage¹⁰. Surgical treatments seemed to effectively recover the cardiopulmonary function but preclude widespread application because of high operation difficulty and surgery-related complications³². Inspired by developments in the treatment of chronic thromboembolic PH³³, PTPA has also reportedly been applied in single cases and small series of patients with TA-associated PAI. In the present study, the PA pressure decreased after PTPA, but 1 patient underwent procedure died of PTPA associated reperfusion pulmonary edema. Similarly, according to previous studies conducted by Dong et al¹⁰ and Yanagisawa et al³⁴, although the therapeutic effect of PTPA on TA-associated PAI and PH was smaller than the effect on chronic thromboembolic PH, the symptoms and hemodynamics were

still markedly improved by PTPA. Procedure-related complication such as pulmonary artery injury or reperfusion pulmonary edema were also acceptable^{10,34}. Therefore, PTPA is a potential useful therapeutic strategy for patients with PH due to TA-associated PAI, but it should be performed cautiously. Future case-control studies are required to evaluate the long-term clinical efficacy of PTPA in patients with PAI-associated PH.

The major limitation of our study is that the diagnosis of PH was mainly dependent up on echocardiography. According to current guidelines, right heart catheterization is required to confirm the diagnosis of PH and identify pre- or post- capillary PH. However, right heart catheterization was difficult to perform on every patient with TA with PAI. Second, the study was conducted in a single institution specializing in cardiovascular disease, and only inpatients who underwent PA angiography were included, this might have resulted in selection bias. Finally, the retrospective study design had the limitations inherent to all retrospective studies. A prospective study is needed to investigate the clinical features and prognosis of patients with TA with PAI.

In conclusion, PAI is not rare in patients with TA. PAI is associated with PH in patients with TA and increases the risk of mortality. Early detection and aggressive treatment of PAI among patients with TA may improve the poor prognosis.

ACKNOWLEDGEMENT

None

REFERENCES

1. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, et al. Takayasu arteritis. *Ann Intern Med* 1994;120:919-29.
2. Numano F, Kobayashi Y. Takayasu arteritis--beyond pulselessness. *Intern Med* 1999;38:226-32.
3. Yamato M, Lecky JW, Hiramatsu K, Kohda E. Takayasu arteritis: radiographic and angiographic

- findings in 59 patients. *Radiology* 1986;161:329-34.
4. Sharma BK, Jain S, Radotra BD. An autopsy study of Takayasu arteritis in India. *Int J Cardiol* 1998;66 Suppl 1:S85-90.
 5. Hotchi M. Pathological studies on Takayasu arteritis. *Heart Vessels Suppl* 1992;7:11-7.
 6. Lupi E, Sanchez G, Horwitz S, Gutierrez E. Pulmonary artery involvement in Takayasu's arteritis. *Chest* 1975;67:69-74.
 7. Toledano K, Guralnik L, Lorber A, Ofer A, Yigla M, Rozin A, et al. Pulmonary arteries involvement in Takayasu's arteritis: two cases and literature review. *Semin Arthritis Rheum* 2011;41:461-70.
 8. Gong J, Yang Y, Ma Z, Guo X, Wang J, Kuang T, et al. Clinical and imaging manifestations of Takayasu's arteritis with pulmonary hypertension: A retrospective cohort study in China. *Int J Cardiol* 2018;276:224-9.
 9. Qin L, Hong-Liang Z, Zhi-Hong L, Chang-Ming X, Xin-Hai N. Percutaneous transluminal angioplasty and stenting for pulmonary stenosis due to Takayasu's arteritis: clinical outcome and four-year follow-up. *Clin Cardiol* 2009;32:639-43.
 10. Dong H, Jiang X, Peng M, Zou Y, Guan T, Zhang H, et al. Percutaneous transluminal angioplasty for symptomatic pulmonary stenosis in Takayasu arteritis. *J Rheumatol* 2014;41:1856-62.
 11. Karadag B, Kilic H, Duman D, Ongen Z, Vural VA, Yazici H. Takayasu disease with prominent pulmonary artery involvement: confusion with pulmonary disease leading to delayed diagnosis. *Mod Rheumatol* 2008;18:507-10.
 12. Sari A, Sener YZ, Firat E, Armagan B, Erden A, Oksul M, et al. Pulmonary hypertension in Takayasu arteritis. *Int J Rheum Dis* 2018;21:1634-9.
 13. Mathai SC, Ryan JJ. The Growing Burden of Pulmonary Hypertension in the Modern Era: A Zebra No More? *Circ Cardiovasc Qual Outcomes* 2018;11:e004536.
 14. Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. *Arthritis Rheum* 1990;33:1129-34.
 15. Hata A, Noda M, Moriwaki R, Numano F. Angiographic findings of Takayasu arteritis: new classification. *Int J Cardiol* 1996;54 Suppl:S155-63.
 16. Qanadli SD, El Hajjam M, Vieillard-Baron A, Joseph T, Mesurolle B, Oliva VL, et al. New CT index to quantify arterial obstruction in pulmonary embolism: comparison with angiographic index and echocardiography. *AJR Am J Roentgenol* 2001;176:1415-20.
 17. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). *Eur Heart J* 2016;37:67-119.
 18. Schmidt J, Kermani TA, Bacani AK, Crowson CS, Cooper LT, Matteson EL, et al. Diagnostic features, treatment, and outcomes of Takayasu arteritis in a US cohort of 126 patients. *Mayo Clin Proc* 2013;88:822-30.
 19. Yamada I, Shibuya H, Matsubara O, Umehara I, Makino T, Numano F, et al. Pulmonary artery disease in Takayasu's arteritis: angiographic findings. *AJR Am J Roentgenol* 1992;159:263-9.
 20. Li J, Sun F, Chen Z, Yang Y, Zhao J, Li M, et al. The clinical characteristics of Chinese Takayasu's arteritis patients: a retrospective study of 411 patients over 24 years. *Arthritis Res Ther* 2017;19:107.

21. Yang L, Zhang H, Jiang X, Zou Y, Qin F, Song L, et al. Clinical manifestations and longterm outcome for patients with Takayasu arteritis in China. *J Rheumatol* 2014;41:2439-46.
22. Wang X, Dang A, Chen B, Lv N, Liu Q. Takayasu arteritis-associated pulmonary hypertension. *J Rheumatol* 2015;42:495-503.
23. Tanigawa K, Eguchi K, Kitamura Y, Kawakami A, Ida H, Yamashita S, et al. Magnetic resonance imaging detection of aortic and pulmonary artery wall thickening in the acute stage of Takayasu arteritis. Improvement of clinical and radiologic findings after steroid therapy. *Arthritis Rheum* 1992;35:476-80.
24. Jin SA, Lee JH, Park JH, Oh JK, Kim MS, Park YK, et al. Endovascular treatment in a patient with left main coronary and pulmonary arterial stenoses as an initial manifestation of Takayasu's arteritis. *Heart Lung Circ* 2015;24:e26-30.
25. Nucifora G, Todiere G, De Marchi D, Barison A, Aquaro GD, Lombardi M, et al. Severe involvement of pulmonary arteries in Takayasu arteritis: magnetic resonance imaging. *Clin Res Cardiol* 2011;100:89-92.
26. Bonilla-Abadia F, Pabon LM, Alvarez AM, Canas CA. Clinical utility of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in Takayasu arteritis -- a report of 3 demonstrative cases. *J Rheumatol* 2013;40:2099.
27. Kobayashi Y, Ishii K, Oda K, Nariai T, Tanaka Y, Ishiwata K, et al. Aortic wall inflammation due to Takayasu arteritis imaged with 18F-FDG PET coregistered with enhanced CT. *J Nucl Med* 2005;46:917-22.
28. Kusunose K, Yamada H, Tomita N, Nishio S, Niki T, Yamaguchi K, et al. Serial imaging changes during treatment of Takayasu arteritis with pulmonary artery stenosis. *Int J Cardiol* 2011;148:e47-50.
29. Addimanda O, Spaggiari L, Pipitone N, Versari A, Pattacini P, Salvarani C. Pulmonary artery involvement in Takayasu arteritis. PET/CT versus CT angiography. *Clin Exp Rheumatol* 2013;31:S3-4.
30. Jiang W, Yang Y, Lv X, Li Y, Ma Z, Li J. Echocardiographic characteristics of pulmonary artery involvement in Takayasu arteritis. *Echocardiography* 2017;34:340-7.
31. Lee GY, Jang SY, Ko SM, Kim EK, Lee SH, Han H, et al. Cardiovascular manifestations of Takayasu arteritis and their relationship to the disease activity: analysis of 204 Korean patients at a single center. *Int J Cardiol* 2012;159:14-20.
32. Tyagi S, Mehta V, Kashyap R, Kaul UA. Endovascular stent implantation for severe pulmonary artery stenosis in aortoarteritis (Takayasu's arteritis). *Catheter Cardiovasc Interv* 2004;61:281-5.
33. Aoki T, Sugimura K, Tatebe S, Miura M, Yamamoto S, Yaoita N, et al. Comprehensive evaluation of the effectiveness and safety of balloon pulmonary angioplasty for inoperable chronic thrombo-embolic pulmonary hypertension: long-term effects and procedure-related complications. *Eur Heart J* 2017;38:3152-9.
34. Yanagisawa R, Kataoka M, Inami T, Fukuda K, Yoshino H, Satoh T. Intravascular imaging-guided percutaneous transluminal pulmonary angioplasty for peripheral pulmonary stenosis and pulmonary Takayasu arteritis. *J Heart Lung Transplant* 2016;35:537-40.

Figure legends

Figure 1. No significant differences in systemic artery involvement were found between

Downloaded on April 9, 2024 from www.jrheum.org

patients with and without PAI (all $p > 0.05$). PAI: pulmonary artery involvement.

Figure 2.(A) Comparison of survival rates between patients with PAI with and without PH (Figure 2A). The risk of all-cause mortality was significantly higher in patients with PH ($p = 0.002$).

(B) Comparison of survival rates of patients with PAI on the basis of PH and LHD. Group 1 vs. Group 2 ($p = 0.161$), Group 1 vs. Group 3 ($p = 0.012$), Group 1 vs. Group 4 ($p = 0.002$), Group 2 vs. Group 4 ($p = 0.029$), Group 3 vs. Group 4 ($p = 0.406$). PAI: pulmonary artery involvement; PH: pulmonary hypertension; LHD: left heart disease. Group 1: Non-PH and Non-LHD; Group 2: Non-PH and LHD; Group 3: PH and Non-LHD; Group 4: PH and LHD.

Table 1. Demographic and clinical characteristics between patients with TA with and without PAI.

	TA with PAI, n=128	TA without PAI, n=66	P Value
Age, years	39.2±12.3	37.7±14.8	0.493
Female, n(%)	111(86.7)	59(89.4)	0.592
Disease duration of TA, months	60(24–156)	66(7–216)	0.757
Hypertension, n(%)	61(47.7)	51(77.3)	<0.001
Hyperlipidemia, n(%)	27(21.1)	25(37.9)	0.012
Diabetes, n(%)	6(4.7)	3(4.5)	>0.999
Stroke, n(%)	5(3.9)	10(15.2)	0.005
Symptoms and signs, n(%)			
Fever	14(10.9)	6(9.1)	0.689
Fatigue	38(29.7)	22(33.3)	0.603
Dizziness	23(18.0)	23(34.8)	0.009
Blurred vision	7(5.5)	5(7.6)	0.564
Limb claudication	25(19.5)	26(39.4)	0.003
Cough	26(20.3)	8(12.1)	0.155
Dyspnea on exertion	95(74.2)	15(22.7)	<0.001
Chest pain	22(17.2)	10(15.2)	0.717
Hemoptysis	26(20.3)	2(3.0)	0.001
Syncope	11(8.6)	6(9.1)	0.908
Pulselessness	65(50.8)	36(54.5)	0.619
Asymmetric blood pressure	90(70.3)	47(71.2)	0.896
Subclavian arteries or aorta bruits	78(60.9)	37(56.1)	0.521
Lower limbs edema	26(20.3)	2(3.0)	0.001
Type of vascular involvement, n(%)			
I	29(22.7)	18(27.3)	0.477
IIa	11(8.6)	1(1.5)	0.062
IIb	11(8.6)	5(7.6)	0.807
III	6(4.7)	1(1.5)	0.426
IV	9(7.0)	10(15.2)	0.071
V	62(48.4)	31(47.0)	0.846
NYHA III/IV, n(%)	52(40.6)	13(19.7)	0.003
ESR>20mm/1h, n(%)	39(30.5)	25(37.9)	0.298
CRP>8mg/L, n(%)	40(31.3)	19(28.8)	0.724
High probability of PH, n(%)	79(61.7)	5(7.6)	<0.001

Data are presented as mean ± SD, median (IQR) or as count (percentage)

TA: Takayasu arteritis; PAI: pulmonary artery involvement; NYHA: New York Heart Association; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; PH: pulmonary hypertension.

Table 2. Angiographic features of PA lesion in 128 TA patients with PAI.

Characteristics	Stenosis, n(%)	Occlusion, n(%)	Poststenotic dilation, n(%)	aneurysm formation, n(%)	In situ thrombosis, n(%)	Total numbers of Patients, n(%)
Right main PA	28(21.9)	20(15.6)	8(6.3)	0(0)	1(0.8)	48(37.5)
Left main PA	15(11.7)	5(3.9)	1(0.8)	0(0)	0(0)	20(15.6)
Right upper lobar PA or its segment	31(24.2)	44(34.4)	5(3.9)	0(0)	0(0)	72(56.3)
Left upper lobar PA or its segment	31(24.2)	25(19.5)	8(6.3)	0(0)	0(0)	49(38.3)
Right middle lobar PA or its segment	22(17.2)	37(28.9)	2(1.6)	1(0.8)	2(1.6)	57(44.5)
Left lingular lobar PA or its segment	20(15.6)	24(18.8)	5(3.9)	1(0.8)	0(0)	44(34.4)
Right lower lobar PA or its segment	34(26.6)	35(27.3)	10(7.8)	1(0.8)	1(0.8)	62(48.4)
Left lower lobar PA or its segment	41(32.0)	37(28.9)	9(7.0)	1(0.8)	1(0.8)	68(53.1)

PA: pulmonary artery; TA: Takayasu arteritis; PAI: pulmonary artery involvement

Table 3. Demographic, clinical characteristics, echocardiography, and therapy between patients with PAI with and without PH

	PAI with PH, n=79	PAI without PH, n=49	P Value
Age, years	42(30–48)	34(28–44)	0.076
Female, n(%)	65(82.3)	46(93.9)	0.067
Onset with respiratory symptoms, n(%)	60(75.9)	8(16.3)	<0.001
Disease duration, mons	72(24–156)	48(12–162)	0.351
Hypertension, n(%)	27(34.2)	34(69.4)	<0.001
Hyperlipidemia, n(%)	13(16.5)	14(28.6)	0.102
Diabetes, n(%)	4(5.1)	2(4.1)	>0.999
Stroke, n(%)	2(2.5)	3(6.1)	0.370
Symptoms and signs, n(%)			
Fever	7(8.9)	7(14.3)	0.339
Fatigue	20(25.3)	18(36.7)	0.169
Dizziness	8(10.1)	15(30.6)	0.003
Blurred vision	3(3.8)	4(8.2)	0.427
Cough	20(25.3)	6(12.2)	0.074
Dyspnea on exertion	75(94.9)	20(40.8)	<0.001
Chest pain	13(16.5)	9(18.4)	0.781
Hemoptysis	21(26.6)	5(10.2)	0.025
Syncope	6(7.6)	5(10.2)	0.609
Claudication	9(11.4)	16(32.7)	0.003
Pulselessness	34(43.0)	31(63.3)	0.026
Asymmetric blood pressure	51(64.6)	39(79.6)	0.070
Subclavian arteries or aorta bruits	41(51.9)	37(75.5)	0.008
Lower limbs edema	21(26.6)	5(10.2)	0.025
NYHA III/IV, n(%)	47(59.5)	5(10.2)	<0.001
Bilateral PA involvement, n(%)	67(84.8)	17(34.7)	<0.001
PAOI	23(20–27)	10(6–15)	<0.001
PaO ₂ <60mmHg, n(%)	23(29.1)	3(6.1)	0.001
ESR>20mm/1H, n(%)	19(24.1)	20(40.8)	0.045
CRP>8mg/L, n(%)	18(22.8)	22(44.9)	0.009
Echocardiography			
Enlargement of LA, n(%)	8(10.1)	9(18.4)	0.182
Enlargement of LV, n(%)	7(8.9)	17(34.7)	<0.001
Enlargement of RA, n(%)	57(72.2)	0	<0.001
Enlargement of RV, n(%)	56(70.9)	0	<0.001
LV hypertrophy, n(%)	7(8.9)	12(24.5)	0.016
Moderate or severe AR, n(%)	4(5.1)	13(26.5)	0.001
Moderate or severe MR, n(%)	2(2.5)	2(4.1)	0.637
TRV, m/s	4.4±0.6	2.7±0.4	<0.001
PASPe, mmHg	89.2±24.5	34.8±9.9	<0.001
LVEF<50%, n(%)	4(5.1)	7(14.3)	0.103

RVSD, n(%)	29(36.7)	0	<0.001
PE, n(%)	11(13.9)	3(6.1)	0.246
Therapy, n(%)			
Corticosteroids	61(77.2)	42(85.7)	0.238
Immunosuppressants	11(13.9)	3(6.1)	0.169
PH-targeted agents	46(58.2)	0	<0.001
PTPA	28(35.4)	0	<0.001

Data are presented as mean ± SD, median (IQR) or as count (percentage)

TA: Takayasu arteritis; PAI: pulmonary artery involvement; PH: pulmonary hypertension; NYHA: New York Heart Association; PA: pulmonary artery; PAOI: pulmonary artery obstruction index; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; PaO₂: arterial oxygen pressure; LA: left atrium; LV: left ventricular; RA: right atrium; RV: right ventricular; AR: aortic regurgitation; MR: mitral regurgitation; TRV: tricuspid regurgitant velocity; PASPe: estimated pulmonary artery systolic pressure; LVEF: left ventricular ejection fraction; RVSD: right ventricular systolic dysfunction; PE: pericardial effusion; PTPA: percutaneous transluminal pulmonary angioplasty.

Table 4. Predictors of mortality in patients with TA with PAI.

Variables	Univariate Analysis		Multivariate Analysis	
	HR(95%CI)	p value	HR(95%CI)	p value
Age	1.046(1.010-1.083)	0.011		
Female	3.036(0.407-22.633)	0.279		
Disease duration	1.005(1.002-1.008)	0.001	1.004(1.000-1.007)	0.047
Hypertension	0.786(0.331-1.866)	0.585		
Hyperlipidemia	0.907(0.331-2.483)	0.849		
Diabetes	1.487(0.342-6.459)	0.597		
NYHA class III / IV	8.072(2.709-24.054)	<0.001	4.201(1.269-13.911)	0.019
Respiratory failure	4.686(1.939-11.324)	0.001	3.601(1.416-9.154)	0.007
PH	7.003(1.637-30.218)	0.009		
LHD	0.834(0.305-2.283)	0.724		
RVSD	6.257(2.630-14.885)	<0.001	3.189(1.207-8.428)	0.019

TA: Takayasu arteritis; PAI: pulmonary artery involvement; HR: hazard ratio; CI: confidence interval;

NYHA: New York Heart Association; PH: pulmonary hypertension; LHD: left heart disease; RVSD: right ventricular systolic dysfunction;




Figure 1. No significant differences in systemic artery involvement were found between patients with and without PAI (all $p > 0.05$). PAI: pulmonary artery involvement.

114x101mm (600 x 600 DPI)




Figure 2.(A) Comparison of survival rates between patients with PAI with and without PH (Figure 2A). The risk of all-cause mortality was significantly higher in patients with PH ($p=0.002$). (B) Comparison of survival rates of patients with PAI on the basis of PH and LHD. Group 1 vs. Group 2 ($p=0.161$), Group 1 vs. Group 3 ($p=0.012$), Group 1 vs. Group 4 ($p=0.002$), Group 2 vs. Group 4 ($p=0.029$), Group 3 vs. Group 4 ($p=0.406$). PAI: pulmonary artery involvement; PH: pulmonary hypertension; LHD: left heart disease. Group 1: Non-PH and Non-LHD; Group 2: Non-PH and LHD; Group 3: PH and Non-LHD; Group 4: PH and LHD.

235x74mm (600 x 600 DPI)